recruited to these trials is the subset of the broader smoking population to which pharmacogenetic tailoring approaches would be provided, efforts to encourage non-motivated smokers to quit may have different pharmacogenetic characteristics; and (b) a lack of ethnic diversity among the sample population—the candidate gene analysis was limited to individuals of European ancestry in order to avoid the effects of population stratification, and the relatively small number of subjects of non-European descent in our population prevented meaningful analysis of this latter group. For this reason, the study findings may not apply to populations of non-European descent. These results will also require replication in independent populations for validation. Ideally, larger populations will also permit a genome-wide analysis of smoking cessation pharmacogenetics, which could identify additional novel loci affecting these phenotypes.
